Sarepta Therapeutics (SRPT) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Sarepta Therapeutics (SRPT) right now is Elevidys franchise durability: Elevidys was the largest growth driver before the safety events, and its trajectory now hinges on a narrower label focused on ambulatory patients plus prescriber and payer confidence. 2026 revenue guidance is ~$1.2B-$1.4B. If that keeps playing out, the setup is favourable; the risk to it is the defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage. No one can predict where SRPT trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Sarepta Therapeutics (SRPT) higher?
1. Elevidys franchise durability
Elevidys was the largest growth driver before the safety events, and its trajectory now hinges on a narrower label focused on ambulatory patients plus prescriber and payer confidence. Sarepta resumed shipments to ambulatory patients in the US after halting broader distribution. Whether revenue stabilizes or keeps eroding is the single biggest swing factor for the stock.
2. Cash-generative base RNA business
The older exon-skipping drugs (Exondys 51, Vyondys 53, Amondys 45) remain approved and revenue-generating, and the company reported the base business produced over $330 million of positive cash flow in 2025. This established franchise gives Sarepta a revenue floor independent of gene-therapy headlines and helps fund the pipeline.
3. Restructuring and self-funding
The 36 percent workforce reduction targets roughly $400 million in annualized savings and a 2026 non-GAAP expense outlook of about $800 million to $900 million. Management has emphasized reaching a self-funded position, with cash and investments reported around $748 million. Cost discipline is meant to preserve optionality while the top line resets.
4. Next-generation pipeline and Roche partnership
Sarepta continues to develop next-generation approaches (including PPMO and additional gene-therapy programs) and collects ex-US economics from Roche on Elevidys. Cohort readouts and pipeline data points are potential catalysts, though several programs sit under heightened FDA scrutiny after the vector-safety events.
What could weigh on SRPT?
The defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage. Regulatory posture toward Elevidys and future gene therapies is uncertain and could further narrow labels or restrict use. Sarepta is heavily concentrated in a single disease (DMD), so a franchise setback has outsized impact. Competition is intensifying from Dyne Therapeutics, Avidity Biosciences, REGENXBIO, Pfizer, and Solid Biosciences, several of which could reach the market in 2026-2027. As a biotech that has cut a third of its staff amid falling revenue, execution, litigation exposure, and financing risk all remain elevated.
Where SRPT trades today
A forecast starts from where the stock actually is. These are SRPT's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for SRPT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a SRPT forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the SRPT guide and whether SRPT is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the SRPT outlook
The bottom line: what is driving Sarepta Therapeutics (SRPT) is Elevidys franchise durability, with 2026 revenue guidance at ~$1.2B-$1.4B. If that keeps playing out the setup is favourable; the risk is the defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage. No one can predict the price, so treat any SRPT forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around SRPT with Walnut
Use Sarepta Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Sarepta Therapeutics (SRPT)?
+
No one can reliably predict where SRPT will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Sarepta Therapeutics higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive SRPT higher?
+
The main growth drivers are Elevidys franchise durability; Cash-generative base RNA business; Restructuring and self-funding. Whether they play out is the real question, not a guaranteed path.
What are the risks to SRPT?
+
The defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage. Regulatory posture toward Elevidys and future gene therapies is uncertain and could further narrow labels or restrict use. Sarepta is heavily concentrated in a single disease (DMD), so a franchise setback has outsized impact. Competition is intensifying from Dyne Therapeutics, Avidity Biosciences, REGENXBIO, Pfizer, and Solid Biosciences, several of which could reach the market in 2026-2027. As a biotech that has cut a third of its staff amid falling revenue, execution, litigation exposure, and financing risk all remain elevated.
Will SRPT stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Sarepta Therapeutics's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is SRPT a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the SRPT "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.